166 related articles for article (PubMed ID: 10339603)
1. Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice.
Ohshima T; Schiffmann R; Murray GJ; Kopp J; Quirk JM; Stahl S; Chan CC; Zerfas P; Tao-Cheng JH; Ward JM; Brady RO; Kulkarni AB
Proc Natl Acad Sci U S A; 1999 May; 96(11):6423-7. PubMed ID: 10339603
[TBL] [Abstract][Full Text] [Related]
2. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
[TBL] [Abstract][Full Text] [Related]
3. Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Jung SC; Han IP; Limaye A; Xu R; Gelderman MP; Zerfas P; Tirumalai K; Murray GJ; During MJ; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2001 Feb; 98(5):2676-81. PubMed ID: 11226298
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
Macedo MF; Quinta R; Pereira CS; Sa Miranda MC
Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450
[TBL] [Abstract][Full Text] [Related]
5. Long-term inhibition of glycosphingolipid accumulation in Fabry model mice by a single systemic injection of AAV1 vector in the neonatal period.
Ogawa K; Hirai Y; Ishizaki M; Takahashi H; Hanawa H; Fukunaga Y; Shimada T
Mol Genet Metab; 2009 Mar; 96(3):91-6. PubMed ID: 19091614
[TBL] [Abstract][Full Text] [Related]
6. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
7. alpha-Galactosidase A deficient mice: a model of Fabry disease.
Ohshima T; Murray GJ; Swaim WD; Longenecker G; Quirk JM; Cardarelli CO; Sugimoto Y; Pastan I; Gottesman MM; Brady RO; Kulkarni AB
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2540-4. PubMed ID: 9122231
[TBL] [Abstract][Full Text] [Related]
8. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer.
Park J; Murray GJ; Limaye A; Quirk JM; Gelderman MP; Brady RO; Qasba P
Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3450-4. PubMed ID: 12624185
[TBL] [Abstract][Full Text] [Related]
9. An in vitro model of Fabry disease.
Shu L; Murphy HS; Cooling L; Shayman JA
J Am Soc Nephrol; 2005 Sep; 16(9):2636-45. PubMed ID: 16033856
[TBL] [Abstract][Full Text] [Related]
10. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice.
Rodrigues LG; Ferraz MJ; Rodrigues D; Pais-Vieira M; Lima D; Brady RO; Sousa MM; Sá-Miranda MC
Neurobiol Dis; 2009 Jan; 33(1):48-56. PubMed ID: 18848893
[TBL] [Abstract][Full Text] [Related]
11. Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.
Shiozuka C; Taguchi A; Matsuda J; Noguchi Y; Kunieda T; Uchio-Yamada K; Yoshioka H; Hamanaka R; Yano S; Yokoyama S; Mannen K; Kulkarni AB; Furukawa K; Ishii S
J Biochem; 2011 Feb; 149(2):161-70. PubMed ID: 20961863
[TBL] [Abstract][Full Text] [Related]
12. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
Choi JO; Lee MH; Park HY; Jung SC
J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
[TBL] [Abstract][Full Text] [Related]
13. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer.
Ziegler RJ; Yew NS; Li C; Cherry M; Berthelette P; Romanczuk H; Ioannou YA; Zeidner KM; Desnick RJ; Cheng SH
Hum Gene Ther; 1999 Jul; 10(10):1667-82. PubMed ID: 10428212
[TBL] [Abstract][Full Text] [Related]
14. Caveolin-associated accumulation of globotriaosylceramide in the vascular endothelium of alpha-galactosidase A null mice.
Shu L; Shayman JA
J Biol Chem; 2007 Jul; 282(29):20960-7. PubMed ID: 17535804
[TBL] [Abstract][Full Text] [Related]
15. Long-term systemic therapy of Fabry disease in a knockout mouse by adeno-associated virus-mediated muscle-directed gene transfer.
Takahashi H; Hirai Y; Migita M; Seino Y; Fukuda Y; Sakuraba H; Kase R; Kobayashi T; Hashimoto Y; Shimada T
Proc Natl Acad Sci U S A; 2002 Oct; 99(21):13777-82. PubMed ID: 12370426
[TBL] [Abstract][Full Text] [Related]
16. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
17. Promoter-specific lentivectors for long-term, cardiac-directed therapy of Fabry disease.
Lee CJ; Fan X; Guo X; Medin JA
J Cardiol; 2011 Jan; 57(1):115-22. PubMed ID: 20846825
[TBL] [Abstract][Full Text] [Related]
18. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
[TBL] [Abstract][Full Text] [Related]
19. α-Galactosidase A-deficient rats accumulate glycosphingolipids and develop cardiorenal phenotypes of Fabry disease.
Miller JJ; Aoki K; Mascari CA; Beltrame AK; Sokumbi O; North PE; Tiemeyer M; Kriegel AJ; Dahms NM
FASEB J; 2019 Jan; 33(1):418-429. PubMed ID: 29979634
[TBL] [Abstract][Full Text] [Related]
20. Enzymatic and functional correction along with long-term enzyme secretion from transduced bone marrow hematopoietic stem/progenitor and stromal cells derived from patients with Fabry disease.
Takenaka T; Hendrickson CS; Tworek DM; Tudor M; Schiffmann R; Brady RO; Medin JA
Exp Hematol; 1999 Jul; 27(7):1149-59. PubMed ID: 10390190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]